Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) EBT Margin (2016 - 2025)

Haemonetics has reported EBT Margin over the past 17 years, most recently at 17.69% for Q4 2025.

  • For Q4 2025, EBT Margin rose 337.0% year-over-year to 17.69%; the TTM value through Dec 2025 reached 17.23%, up 524.0%, while the annual FY2025 figure was 15.58%, 398.0% up from the prior year.
  • EBT Margin for Q4 2025 was 17.69% at Haemonetics, up from 15.67% in the prior quarter.
  • Over five years, EBT Margin peaked at 21.4% in Q1 2025 and troughed at 12.17% in Q2 2021.
  • A 5-year average of 10.88% and a median of 13.02% in 2023 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: tumbled -2138bps in 2021 and later skyrocketed 1796bps in 2022.
  • Year by year, EBT Margin stood at 8.3% in 2021, then skyrocketed by 67bps to 13.83% in 2022, then decreased by -5bps to 13.09% in 2023, then grew by 9bps to 14.32% in 2024, then increased by 24bps to 17.69% in 2025.
  • Business Quant data shows EBT Margin for HAE at 17.69% in Q4 2025, 15.67% in Q3 2025, and 14.05% in Q2 2025.